Elevance Health Inc.

(New York Stock Exchange)
Back to all articles
Bullish +75

Elevance Health raises 2026 guidance for Elevance Health stock

Dividend Guidance raised Leadership change AI-generated analysis

πŸ“ˆ Elevance Health raised its full-year 2026 diluted earnings-per-share guidance to at least USD 22.00 following strong third-quarter results.

πŸ’° The company increased its adjusted diluted earnings-per-share guidance for 2026 to a minimum of USD 29.00, reflecting improved profitability expectations.

πŸ“Š Third-quarter operating revenue reached USD 50.40 billion, demonstrating significant scale and consistent top-line growth for the insurer.

πŸ’΅ Elevance Health upgraded its full-year 2026 operating cash flow guidance to at least USD 6.50 billion, highlighting strong liquidity generation.

πŸ₯ The benefit expense ratio stood at 90.6 percent for the quarter, indicating efficient management of healthcare claims and costs.

πŸ‘” Jeff Park will assume the role of President of Carelon effective December 1, 2026, expanding leadership in the company's care management segment.

πŸ’Έ Elevance Health declared a fourth-quarter dividend of USD 1.72 per share, payable on December 18, 2026, to shareholders of record as of December 4.

Bullish Signals
  • Elevance Health raised its full-year 2026 diluted earnings-per-share guidance to at least USD 22.00, signaling strong confidence in future profitability.
  • The company increased its adjusted diluted earnings-per-share guidance for 2026 to at least USD 29.00, further validating its operational execution.
  • Third-quarter operating revenue of USD 50.40 billion demonstrates robust top-line growth and market dominance in the health insurance sector.
  • Elevance Health upgraded its full-year 2026 operating cash flow guidance to at least USD 6.50 billion, providing a strong liquidity buffer for investments or buybacks.
  • A benefit expense ratio of 90.6 percent in the third quarter reflects disciplined cost control and effective claims management strategies.
  • The appointment of Jeff Park as President of Carelon strengthens the company's strategic position in high-growth care management services.
Full Analysis
Elevance Health reported strong third-quarter financial results and raised its full-year guidance for 2026. The company posted third-quarter operating revenue of USD 50.40 billion, significantly exceeding market expectations. Consequently, the firm increased its diluted earnings-per-share guidance to at least USD 22.00 and adjusted diluted earnings-per-share guidance to at least USD 29.00 for the full year. In addition to raising earnings forecasts, Elevance Health upgraded its full-year operating cash flow guidance to a minimum of USD 6.50 billion. The company also reported a benefit expense ratio of 90.6 percent for the quarter, indicating effective cost management within its healthcare operations. These positive financial metrics reflect a robust operational performance during the third quarter of 2026. Beyond financial guidance, Elevance Health announced key leadership changes and shareholder returns. Jeff Park is set to become President of Carelon effective December 1, 2026, signaling strategic growth in its care management division. Furthermore, the company declared a fourth-quarter dividend of USD 1.72 per share, payable on December 18, 2026, reinforcing its commitment to returning value to shareholders.